What does Glivec ruling imply for generics? My piece in Sunday ET

In case some of you were waiting for Apothecury's take on the Glivec judgement, I was waiting for this piece that I did for the Sunday Economic Times to be published. In a nutshell, in the article I explain why, as far as India's generics industry is concerned, the Glivec outcome is not really a …

Advertisement

Guest column on India & drug patents: Can the US force policy change?

The pharma giant Pfizer wants the US government to act more aggressively to defend the interests of the research-based pharmaceutical sector in India. Will it succeed? The path from lobbying in Washington, D.C, to a change of policy in India is a long and uncertain one involving multiple steps. First, Pfizer needs to convince Congress …

Guest column : Indian patent rulings and impact on emerging economies

Recent Indian patent rulings, as well as those to come, are changing the intellectual property rights (IPR) landscape for emerging economies. They are watched with keen interest by other developing nations to measure the response of innovative pharmaceutical firms and the global community. Whether or not they are precedent-setting remains to be seen.  Reflecting on the …

Beyond Glivec : Balancing innovation and public health

I'd like to introduce a guest column by Dr Kristina Lybecker, Associate Professor of Economics at Colorado College in Colorado Springs. Kristina is an economist with a PhD from the University of California at Berkeley. She specialises in innovation and intellectual property rights and has been writing on these issues for 12 years. She is …

Guest post : Why the compulsory licence to Natco is a bad idea

I'd like to introduce a guest post from Ranga Iyer, former MD of Wyeth Limited and a drug industry veteran. He is currently an independent advisor to Indian and foreign drug companies on strategy, policy, as also mergers and acquisitions.  In 2009, Ranga, then president of the Organisation of Pharmaceutical Producers of India,  was ranked …